Currently, the main prostate cancer treatments are: radical prostate surgery, iodine 125 particle implantation therapy, endocrine therapy, and radiotherapy. According to the stage of prostate cancer, the treatment options used are as follows: Stage A, cancer discovered incidentally during the treatment of prostate enlargement, the lesions are limited, most of them are well differentiated, most patients have stable disease and slow progression, and only about 1% may die from cancer. If no treatment is given, the tumor may progress in 35% of patients, so radical prostatectomy, iodine 125 particle implantation therapy or radiation therapy should be considered. Most of the stage B1 tumors are well differentiated, but 5%-20% of patients are found to have lymphatic metastasis at the time of surgery, so radical prostatectomy and iodine 125 particle implantation treatment should be performed, and the 15-year cancer-free survival rate is 50%-70% after treatment. In stage B2, about 50% of patients have invaded the seminal vesicles and 25%-35% of patients have lymph node metastasis, so radical resection of prostate cancer plus pelvic lymph node dissection, iodine 125 particle implantation, orchiectomy, endocrine therapy, radiation therapy, etc. The 15-year cancer-free survival rate after radical surgery in stage B2 is 25%. There is no unified opinion on the treatment of stage C. Therefore, the treatment is more difficult at that time, and most of the pelvic lymph nodes have metastasis. Generally, the following methods of treatment are used: ① For patients who are old and frail and in poor general condition, it is suitable to use extended range external radiotherapy; ② Endocrine therapy (including double orchiectomy), after downgraded treatment, extended range external radiotherapy and combined application of radical surgery for prostate cancer; ③ Iodine 125 particle implantation therapy is also suitable for lymph node metastasis that cannot be operated, radiotherapy and endocrine therapy are ineffective and ③Iodine 125 particle implantation is also suitable for treatment of lymph node metastasis and distant metastases that are inoperable and where radiotherapy and endocrine therapy are not effective. Endocrine therapy, iodine 125 particle implantation, chemotherapy and biological therapy are the main treatments for stage D. For stage D0 and D1, pelvic lymph node dissection can be performed, and early application of endocrine therapy can prolong the survival time with tumor, and the 5-year survival rate is about 30%. Bone metastasis can easily occur in prostate cancer, and those with bone metastasis should be treated with strontium 89-bone metastasis therapy, combined with bisphosphonates if necessary.